Neutrophil Extracellular Traps in Arterial and Venous Thrombosis

Elodie Laridan, MSc1 Kimberly Martinod, PhD1 Simon F. De Meyer, PhD1

1Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

Address for correspondence Simon De Meyer, PhD, Laboratory for Thrombosis Research, KU Leuven Campus Kulak Kortrijk, E. Sabbelaan 53, 8500 Kortrijk, Belgium (e-mail: simon.demeyer@kuleuven.be).

Abstract

Thrombotic complications are still a major health risk worldwide. Our view on the pathophysiology of thrombosis has significantly changed since the discovery of neutrophil extracellular traps (NETs) and their prothrombotic characteristics. Generated by neutrophils that release their decondensed chromatin as a network of extracellular fibers, NETs promote thrombus formation by serving as a scaffold that activates platelets and coagulation. The thrombogenic involvement of NETs has been described in various settings of thrombosis, including stroke, myocardial infarction, and deep vein thrombosis. The aim of this review is to summarize existing evidence showing the presence of NETs in human thrombus material. Following an introduction on NETs and their role in thrombus formation, the authors address studies showing the presence of NETs in arterial or venous thrombi. In addition, they focus on potential novel therapeutic opportunities to resolve or prevent thrombosis by targeting NETs.

Keywords

- NETs
- thrombosis
- neutrophil
- stroke
- venous thromboembolism
- myocardial infarction

In the last decade, neutrophil extracellular traps (NETs) have significantly changed our view on thrombosis. Thrombosis is caused by blood clots that hamper normal blood flow in arteries or veins, leading to several pathologies including ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). With one in four people dying worldwide from thrombotic conditions, thrombosis is a major contributor to global disease burden. To improve prevention, diagnosis, and treatment of thrombosis, a good understanding of its underlying mechanisms is essential. Interestingly, NETs have been identified as new DNA-based players in blood clot formation and thrombosis. Evidence of NETs being present in thrombi retrieved from thrombosis patients is growing and the impact of NETs in thrombosis is gaining increased attention. NETs have been found in different settings of thrombosis, including stroke, myocardial infarction, and deep vein thrombosis (DVT). In this review, we summarize current knowledge on the presence of NETs found in human thrombi. After introducing NETs and their role in thrombus formation, we address studies showing the presence of NETs in arterial or venous thrombi. We also discuss the potential clinical implications and novel therapeutic opportunities of targeting NETs in thrombosis.

Neutrophil Extracellular Traps

Neutrophil extracellular traps were first discovered as a novel immune defense mechanism of neutrophils. In 2004, Brinkman et al described the ability of neutrophils to release decondensed chromatin that is decorated with granular proteins, forming a network of extracellular fibers. NETs create a physical barrier that prevents the spread of pathogens and facilitates killing microbes by high concentrations of antimicrobial proteins and phagocytosis by other phagocytes. Other than necrosis or apoptosis, NETosis is a well-orchestrated form of cell death during which neutrophils undergo important changes in their morphology after stimulation by a variety of agonists including pathogens, platelets, and noninfectious inflammatory stimuli. First, the nucleus loses its characteristic nuclear lobulation and subsequently swells (Fig. 1). Second, due to swelling, the integrity of nuclear membrane as well as of granular membrane is lost, allowing mixing of...
chromatin with cytoplasmic and granular contents. Finally, the cytoplasmic membrane is compromised, resulting in release of NET into the extracellular space. Although the exact steps in NET formation are still poorly understood, some key players have been identified, including reactive oxygen species (ROS), granulocyte enzymes such as myeloperoxidase (MPO), and neutrophil elastase (NE), and involvement of enzyme peptidylarginine deiminase 4 (PAD4). A well-described aspect of NETosis is the citrullination of histones catalyzed by PAD4, which rapidly enters the nucleus, and nuclear translocation of NE and MPO drive chromatin decondensation and nuclear swelling accompanied by the loss of internal nuclear membranes. NETs are then released into the extracellular space, providing procoagulant/prothrombotic activity through various mechanisms linked to NET components. Histones induce endothelial cell cytotoxicity, inhibit protein C activation promoting thrombin generation, and induce platelet aggregation either directly or via fibrinogen. Serine proteases inhibit TFPI, promoting tissue factor and factor XII–dependent coagulation and fibrin formation. These coagulation factors can also directly bind to NETs. NETs also form a scaffold for platelet adhesion, and VWF and fibrinogen binding, and thus targeting of thrombi with DNase represents a promising therapeutic approach in thrombosis. APC, activated protein C; CatG, cathepsin G; HMGB1, high mobility group box 1 protein; Cit., citrullinated; FXII, factor XII; Jak/STAT, Janus kinase/signal transducer and activator of transcription proteins; MPO, myeloperoxidase; NE, neutrophil elastase; PAD4, peptidylarginine deiminase 4; PSGL-1, P-selectin glycoprotein ligand 1; RAGE, receptor for advanced glycation end products; ROS, reactive oxygen species; TF, tissue factor; TFPI, tissue factor pathway inhibitor; TLR2/4, toll-like receptors 2 and 4; VWF, von Willebrand factor; WPB, Weibel-Palade body.
Neutrophil Extracellular Traps and Thrombosis

The concept of immunothrombosis describes the interaction of the innate immune system and the activation of coagulation. The specific contribution of neutrophils in thrombus formation is only recently becoming better understood. Together with platelets, neutrophils are among the first cells recruited to sites of injury and/or infection. Neutrophils can limit the dissemination of microbial infections as part of their host defense mechanisms by promoting blood coagulation, for example, by enhancing fibrin deposition. This fibrin/NET network prevented bacterial invasion into surrounding tissue from the liver microvasculature, and disruption of the NET scaffold promoted systemic dissemination of bacteria. Dysregulation or excessive stimulation, in particular within the vasculature, can, however, lead to pathological thrombotic processes. Neutrophils thus regulate thrombosis via several mechanisms in which NETs play a central role.

One of the main ways by which NETs promote thrombosis is by forming a scaffold for adhesion of platelets, red blood cells (RBCs), and platelet adhesion molecules such as fibronogen, von Willebrand factor (VWF), and fibronectin. This scaffold not only forms a structural basis but many of its components can also actively trigger platelet activation and blood coagulation. Histones H3 and H4 are highly cytotoxic to endothelial and epithelial cells, while they can also trigger platelet aggregation. Histones are able to interact with platelets via fibrinogen or directly via Toll-like receptors (TLR) 2 and 4, thus resulting in platelet activation and local increase of thrombin generation. By binding to thrombomodulin, histones also prevent the activation of activated protein C (APC), thus boosting further thrombin generation. In addition, NETs promote both the intrinsic and extrinsic coagulation pathway, mainly through the activity of neutrophil serine proteases. NE and cathepsin G, which are also present on NETs, enhance tissue factor- and factor XII-driven coagulation via proteolysis of tissue factor pathway inhibitor (TFPI). NETs also directly bind factor XII and, with the cooperation of platelets, support its activation to factor Xla. Interestingly, complete NET complexes do not have the same degree of procoagulant effect as their separate DNA and histone components, which individually have been shown to be more potent promoters of coagulation. Possibly, the tight packaging of histones and DNA into nucleosomes partly reduces the ability to interact with the coagulation system.

The interaction between NETs and platelets and, in turn, between activated platelets and neutrophils can stimulate the vicious circle leading to pathological thrombus formation. Indeed, activated platelets were shown to promote NETosis via pathways that are currently not completely elucidated, but most likely include P-selectin/P-selectin glycoprotein ligand 1 interaction, and release of damage-associated molecular patterns, such as high-mobility group box 1 protein (HMGB1) and platelet TLRs. Most of the evidence on NETs-mediated thrombosis is derived from animal studies or in vitro studies using single cell interactions. Whether or not NETs are directly involved in human pathological thrombus formation is less well studied. Yet, studies on retrieved human thrombus material have started to reveal that NETs are indeed important constituents of human thrombi. In the next sections, current knowledge regarding the presence of NETs in both arterial and venous thrombi retrieved from patients is discussed in more detail.

Neutrophil Extracellular Traps in Arterial Thrombi

Increasing evidence from studies on human thrombi indicates that NETs are part of arterial thrombi in various thrombotic pathologies, including myocardial infarction and ischemic stroke. Already before the discovery of NETs, it was shown that neutrophils were important constituents of culprit lesions causing acute myocardial infarction. More recent histological studies using novel specific markers revealed that NETs are also abundant throughout coronary thrombi retrieved from patients with acute myocardial infarction. A multicenter European study showed that neutrophils and NETs are also hallmarks of thrombosis retrieved from patients with stent thrombosis after percutaneous coronary intervention. NETs in coronary thrombi were typically identified via histochemical and immunohistochemical stainings for extracellular DNA and histones, together with a neutrophil marker such as MPO or NE. NETs were found in close proximity of platelets, suggesting that activated platelets actively contribute to the incorporation of NETs in coronary thrombi, for example, via HMGB1. Served as a scaffold for platelets, erythrocytes, and fibrin, NETs possibly contribute to thrombus growth and stabilization. Indeed, NETs were frequently observed in thrombi that were only a couple of days old, but not in older, more organized coronary thrombus specimens. Importantly, Mangold et al found that coronary thrombus NET burden correlated positively with infarct size and negatively with ST-segment resolution, indicating the potential clinical relevance of NETs in myocardial infarction. Also in ischemic stroke, NETs have been identified as an important constituent of occluding thrombi. We recently described the presence of NETs in 68 thrombi that were retrieved from ischemic stroke patients via endovascular thrombectomy. In these cerebral occlusions, neutrophils were abundant, and NETs were found in all thrombi. NETs were visualized and identified via staining for extracellular chromatin, NE, and citrullinated histone H3 (H3Cit). Since ischemic stroke can be caused by thrombi from different origins depending on stroke etiology, it is interesting to correlate thrombus composition with etiology. Although we did not find a correlation between presence of neutrophil and stroke etiology, other studies showed that stroke thrombi from cardioembolic origin are particularly rich in white blood cells. Accordingly, NETs were more abundant in stroke thrombi of cardioembolic origin compared...
with noncardioembolic thrombi. The reason for such differences remains unclear, but the local environment (e.g., stasis vs. high shear) and thrombus maturation stage may in part influence the presence of NETs in the retrieved thrombi. We indeed found a higher presence of NETs in more mature, older stroke thrombi compared with younger, fresh thrombi. Ducroux et al. recently performed histological analysis on 34 human ischemic stroke thrombi and similarly found that NETs were abundantly present in all thrombi via triple costaining positive for DNA, MPO, and citrullinated histone H4. Interestingly, the presence of NETs was positively correlated with the length of thrombectomy procedure and number of device passes performed to achieve successful recanalization. Hence, NETs may participate in the interaction between thrombus and arterial wall, or between thrombus and thrombectomy device, further highlighting the potential clinical importance of NETs in thrombosis.

Besides myocardial infarction and ischemic stroke, NETs have also been found in other arterial pathological conditions, in particular in intraluminal thrombi derived from patients with abdominal aortic aneurysm (AAA). Detection of DNA-histone complexes was lower in older, more mature AAA thrombi (detected via computed tomography at least 1 year before retrieval), corresponding to reduced overall cellularity and higher collagen detection. Again, this suggests that NETs may play a role during thrombus formation and organization, which in later phases evolves to tissue remodeling. The differentiation of fibroblasts to collagen-producing myofibroblasts was induced by exposure to NETs in vitro, but the direct contribution of NETs in the context of arterial thrombosis has not yet been investigated. Importantly, infections can accelerate neutrophil recruitment and activation, leading to a more pronounced involvement of NETs in thrombosis. This was, for example, shown in patients with AAA, where *Porphyromonas gingivalis* infection (involved in chronic periodontitis) promoted neutrophil recruitment and NET formation and inhibited healing. Infection-driven thrombosis also led to NETs’ detection of intraluminal lung thrombi in patients with acute interstitial pneumonitis and sepsis.

**Neutrophil Extracellular Traps in Venous Thrombi**

Venous thromboembolism comprises DVT, blood clots in large veins, and pulmonary embolism (PE), blood clots in pulmonary arteries likely originating as embolization of a venous thrombus. Animal models provided the first insight into the presence of NETs in venous thrombi. Histological analysis of a thrombus from an iliac vein balloon catheterization model in baboons revealed an extracellular chromatin core. Over the course of thrombus development, cell-free DNA in plasma became elevated. This was also seen in the inferior vena cava DVT mouse model induced by flow restriction in mice along with the identification of citrullinated histones. These findings provided a basis for examining NETs in human VTE patients.

---

**Fig. 2** NETs in stroke thrombi. Thrombi retrieved from stroke patients were analyzed via histology. The presence of citrullinated histones was analyzed via immunohistochemistry using an antibody against citrullinated histone H3 (H3Cit). (A) Zones of nuclear material that appeared extracellular were often observed on hematoxylin and eosin (H&E) staining (arrowheads). (B, C) These chromatin strands corresponded with areas staining positive for H3Cit (B, brown staining) and neutrophil elastase (NE; C, brown staining). Neutrophils undergoing complete NETosis were also identified via triple costaining of H3Cit (green), the granulocyte marker CD66b (red), and DNA (DAPI, blue), as shown in panel D. Scale bars: 10 μm in panels A, B, and C and 5 μm in panel D. (Adapted and reproduced with permission from Laridan et al.)

---
A case report of a patient with microscopic polyangiitis (MPA) complicated with VTE identified NETs by immunostaining for citrullinated histones in both the affected kidney and also a deep vein thrombus at autopsy. A quantitative comparison of this thrombus with another patient’s postoperative PE specimen showed that it contained a higher amount of NETs, which raised the possibility that certain venous thrombi can contain more NETs than others. As discussed, this could be due to the difference in etiology of the thrombus, here an autoimmune vasculitis, or also potentially due to the thrombus age or organization stage. It is often difficult to assess the true age of a thrombus prior to the appearance of symptoms, but histological examination can provide insight regarding the organization stage(s) of the thrombus. This was the basis for the study of Savchenko et al, where 16 VTE thrombi originating from 11 patients with DVT, PE, and/or an inferior vena cava filter thrombus were analyzed. After scoring the organization stage based on the Masson trichrome staining, consecutive sections were analyzed for the presence of neutrophils and citrullinated histone H3 (H3Cict) as a marker of extracellular NET structures or NETting neutrophils. Interestingly, NETs were predominantly found in the organizing parts of the thrombus and were much less present in already organized thrombi regions. This indicates that NET formation is likely transient, taking place with recruitment of neutrophils into the thrombus, and that as the thrombus matures, extracellular NETs are degraded and replaced with a collagen network. After thrombus formation, thrombus maturation into a tissue-like structure takes place over the following weeks, finally containing primarily collagen, fibroblasts, microvessels, and few leukocytes or platelets. As NETs can stimulate fibrotic remodeling, this provides another mechanism by which NETs could contribute to venous thrombus pathogenesis, by promoting development of a stable thrombus which is difficult to resolve with the body’s endogenous thrombolytic pathways. This is of particular relevance for the sequelae of VTE, such as postthrombotic syndrome or chronic thromboembolic pulmonary hypertension, and thus is of great interest for future investigation. Furthermore, as NETs could impact thrombus stability, a better understanding of thrombus composition could allow us to better predict the risk for DVT embolization. The effect of degree of NETs within a thrombus on embolization has not yet been investigated, and is worthy of study.

The relative contribution of NETs in venous versus arterial thrombosis is still unknown. Mangold et al examined NETs by immunostaining for DNA–histone complexes and performed a side-by-side comparison of 30 coronary artery thrombi and 7 deep vein thrombi, in both cases excised by thrombectomy. Based on this analysis, it was proposed that arterial thrombi could contain more NETs than venous thrombi. However, it is clear that there is a great heterogeneity in the content of NETs among different patients, and thus a study involving a larger number of venous thrombi is needed to fully address this question.

**Circling Biomarkers of NETs and Thrombosis**

The concept of NETs contributing to thrombosis is supported by an increasing number of studies showing circulating biomarkers of NETosis in thrombotic pathologies. Cell-free DNA, MPO–DNA complexes, nucleosomes, and circulating citrullinated histones are indeed increased in various conditions, including sepsis, small vessel vasculitis, venous thrombosis, coronary atherosclerosis, and stroke. Interestingly, plasma levels of NETs markers often correlate with disease severity, as was shown in ischemic stroke and VTE. However, since many of these markers, with the exception of citrullinated histones, are not specific for NETosis and may also increase during general tissue damage and necrosis, suitable assays for specifically measuring circulating NET components or NET degradation products would be of high interest for future studies. Although NET biomarkers have been measured in venous and arterial thrombosis patients separately, a study comparing the two has not yet been performed. Measuring NET biomarkers may be of broader clinical relevance, such as in predicting the progression to sepsis in burn patients.

As different types of bacteria induce varying amounts of NET release and cell-free DNA strongly correlates with progression in severe sepsis, comparing NET biomarkers across different infectious sources in sepsis linked to outcome could be valuable.

**Neutrophil Extracellular Traps: A New Therapeutic Target?**

The involvement of NETs in both arterial and venous thrombosis creates the interesting possibility to develop novel therapeutic strategies targeting NETs, to either reduce thrombosis or improve thrombolysis. As a scaffold for thrombus formation, NETs can contribute to overall thrombus stability, conferring resistance to thrombolysis. Hence, degradation of NETs structure, in addition to fibrin breakdown via the fibrinolytic system, could become a promising thrombolytic option. NETs are composed of decondensed chromatin networks and are thus vulnerable to nuclease activity. Certain nuclease-producing microbes use such nucleases to evade the toxic effect of NETs. In addition, host DNAses, such as DNase1 and DNase1-like 3, were recently shown to counteract the deleterious effects of intravascular NET formation. DNase1 is the predominant nuclease in plasma. After finding the presence of NETs in thrombi from ischemic stroke patients, we tested whether pharmacological breakdown of NETs using DNase1 could enhance thrombus dissolution. Although treatment of stroke thrombi with tissue plasminogen activator (t-PA) alone induced gradual, partial lysis of the thrombi, addition of DNase1 significantly accelerated ex vivo lysis. These findings showed that DNase1 can promote ex vivo stroke thrombus dissolution, providing proof of concept to target NETs as a novel prothrombolytic strategy in ischemic stroke. Similar results were recently reported by Ducroux et al, who
in addition showed that treatment with DNase1 alone had no thrombolytic effect on ischemic stroke thrombi. Indeed, combination of both fibrinolysis and nuclease activity is needed to induce successful thrombolysis. When blood clots were generated in vitro in the presence of activated neutrophils releasing NETs, treatment with t-PA alone was effective to degrade most of the fibrin, but resulted in clots that were still held together by a scaffold of extracellular DNA. Furthermore, DNA and histones were shown to modify the structure of fibrin into thicker fibrin fibers, thus resulting in increased resistance to mechanical and enzymatic destruction. Interestingly, DNase1 activity may benefit from the plasminogen system, as plasmin can degrade histones, thereby facilitating chromatin degradation by DNase1.

Addition of DNase1 also accelerated ex vivo tPA-mediated thrombus lysis on coronary thrombi retrieved from patients with acute coronary syndrome, thus suggesting a broad therapeutic potential of DNase1. Importantly, DNase1 already is a safe, low-cost, U.S. Food and Drug Administration (FDA)-approved drug routinely used for cystic fibrosis to clear extracellular DNA in the lungs. Combination of DNase1 with t-PA could potentially allow decreasing the dose of t-PA utilized, so limiting its side effects and potentially increasing its therapeutic time window. In particular, DNase1 could be used in combination with the VWF-cleaving enzyme ADAMTS13, of which we previously demonstrated thrombolytic activity, able to dissolve t-PA-resistant cerebral occlusion in a mouse model of ischemic stroke.

In addition to digesting NETs, another potential therapeutic approach is neutralizing their harmful components. Heparin has been shown to dismantle NETs and to neutralize to harmful effects of histones, probably due to electrostatic interactions between negatively charged heparin and histones. APC cleaves histones, thereby reducing their cytotoxicity, an effect that can be potentiated via thrombomodulin alfa-mediated increase of APC generation. To circumvent the potential bleeding risk associated with the anticoagulant properties of heparin and APC, non-anticoagulant variants could become of high interest.

Recurrent thrombosis is a concern in both arterial and venous thrombosis. In patients who have previously experienced a thrombotic event, prevention of NET formation could be beneficial. Inhibition of PAD4 may become a promising strategy, as PAD4 deficiency reduced thrombotic occurrence in a mouse model of venous thrombosis. Importantly, PAD4 deficiency did not lead to increased susceptibility to bacterial infection in animal models, indicating that this approach would not likely lead to a detrimental immunosuppressive effect due to a lack of NETs. Selective PAD4 inhibitors that prevent NET formation have been developed, and further research is needed to validate their therapeutic potential. Also, pharmacological inhibition of Janus kinase (JAK) signaling has been proposed to reduce NETosis and thrombosis. Ruxolitinib, an FDA-approved inhibitor of JAK, abrogated NET formation and reduced thrombosis in a mouse model of deep vein stenosis. Although the exact mechanisms by which the JAK pathway interferes with NET formation is not still completely clear, regulation of PAD4 is one hypothesis. While patients receiving ruxolitinib had a lower risk of VTE events in the RESPONSE trial, more studies, specifically designed to evaluate NETosis and its link with thrombotic risk in ruxolitinib-treated patients, would be of interest in the future.

Conclusion

Neutrophil extracellular traps have become undeniable actors in the field of thrombosis and hemostasis. NETs regulate thrombosis in different ways and are implicated in the pathophysiology of both arterial and venous thrombotic complications. Without a doubt, future studies will further fine-tune our knowledge on temporal and spatial processes of neutrophil-driven thrombus formation and maturation. This information will become highly valuable for developing novel antithrombotic therapies. Pharmacological disassembly and degradation of NETs in thrombi can enhance acute thrombolysis. In addition, preventing the formation of NETs can reduce thrombogenicity, which might become beneficial in thrombosis prevention. Preclinical and clinical studies investigating these new therapeutic opportunities are now needed to fully understand the efficacy and safety of targeting NETs in thrombosis.

Conflicts of Interest

E.L. has no conflict of interest to disclose. S.F.D.M. and K.M. are inventors on the granted patent US9642822 covering the targeting of NETs in thrombosis. K.M. is an inventor on U.S. patent application 62/594,266 that covers the use of ruxolitinib and inhibition of JAK-STAT signaling to inhibit the formation of NETs.

Acknowledgments

This work was supported by the Fonds voor Wetenschappelijk Onderzoek – Vlaanderen (Strategic Basic Research Doctoral Grant 1S25216N to E.L. and research grants G.0A86.13, G.0785.17, and 1509216N to S.F.D.M), by an “Onderzoekstoelag” grant from KU Leuven (OT/14/099 to S.F.D.M) and by a research grant from the Queen Elisabeth Medical Foundation (to S.F.D.M). K.M. is the recipient of a fellowship from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 747993.

References


NETs in Human Thrombi
Laridan et al. 93

50 Borissoff JJ, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013;33(08):2032–2040
59 Van Zifflé JA, Lowell CA. Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection. Blood 2009;114(23):4871–4882
64 Napiere M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis Rheum 2004;50(06):1873–1883